Last reviewed · How we verify

EFV plus ABC/3TC or RPV/TDF/FTC — Competitive Intelligence Brief

EFV plus ABC/3TC or RPV/TDF/FTC (EFV plus ABC/3TC or RPV/TDF/FTC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

EFV plus ABC/3TC or RPV/TDF/FTC (EFV plus ABC/3TC or RPV/TDF/FTC) — Juan A. Arnaiz. This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EFV plus ABC/3TC or RPV/TDF/FTC TARGET EFV plus ABC/3TC or RPV/TDF/FTC Juan A. Arnaiz phase 3 Antiretroviral combination therapy (NNRTI + NRTIs) HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild Sofosbuvir, Ribavirin, and Stribild Saint Michael's Medical Center marketed Direct-acting antiviral (DAA) combination; antiretroviral combination HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
Abacavir sulfate, Lamivudine and Zidovudine Abacavir sulfate, Lamivudine and Zidovudine National Institute of Allergy and Infectious Diseases (NIAID) marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
AZT AZT Johns Hopkins Bloomberg School of Public Health marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
"Raltegravir" and "Zidovudine" "Raltegravir" and "Zidovudine" Universidad Peruana Cayetano Heredia marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor) HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine)
Tenofovir/Emtricitabine Tenofovir/Emtricitabine Bristol-Myers Squibb marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination HIV reverse transcriptase
TDF/3TC/EFV or DTG or NVP TDF/3TC/EFV or DTG or NVP MU-JHU CARE marketed Antiretroviral combination therapy (NRTI + NNRTI or INSTI) HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NRTIs) class)

  1. Institut de Recherche pour le Developpement · 1 drug in this class
  2. Juan A. Arnaiz · 1 drug in this class
  3. University of Cologne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EFV plus ABC/3TC or RPV/TDF/FTC — Competitive Intelligence Brief. https://druglandscape.com/ci/efv-plus-abc-3tc-or-rpv-tdf-ftc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: